ArticleMedical journal, Armed Forces India2025
Assessment of programmed death ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and carcinoma cervix.
Article in Medical journal, Armed Forces India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carcinoma cervix is a significant public health issue in low- and middle-income nations. Despite the availability of aggressive cytological screening tests and increasing accessibility of the Human Papilloma Virus vaccine, a significant proportion of patients in our country still present with locally advanced cervical cancer. The objective of this study was to estimate the prevalence of programmed death ligand 1 (PD-L1) immunoexpression in cervical intraepithelial neoplasia and carcinoma cervix and study the distribution of clinicopathological features and recurrence of cervical cancer with respect to PD-L1 status. Methods: A total of 140 patients were included in this multicentric ambidirectional study. Immunohistochemical analysis for PD-L1 was performed on paraffin-embedded, formalin-fixed sections using 22C3 PharmDx assay (Dako) and tumour proportion score was calculated. PD-L1 expression status concerning the distribution of clinicopathological features was further studied. Results: This study included 133 cases of cervical carcinoma and 7 cases of cervical intraepithelial neoplasia (140 cases), with a prevalence of PDL1 positivity in 31.4% of cases with 15% (n = 21) tumours high positive, 16.4% (n = 23) low positive and 68.6% (n = 96) negative for PD-L1. It was observed that all cases with PD-L1 positivity were characterized as squamous cell carcinoma. The mean age of subjects was 56.74 ± 11.52 years. PD-L1 high positivity was observed in 26.7% of individuals in the age group >70 years, 21.7% of grade 3 tumours, 11.4% of tumours exceeding 4 cm in size, and 33.3% of cases showing recurrence. PD-L1 immunoexpression did not demonstrate a significant association with the patient's age, tumour grade and stage, as well as recurrence. Conclusion: It is envisaged that anti-PD-L1 immunotherapy could show promising antitumour activity and early survival rates among patients with cervical squamous cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.